{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:29:44Z","timestamp":1788953384555,"version":"build-2803163510"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T00:00:00Z","timestamp":1618617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We investigatedthe association between time-averaged area under the curve (AAUC) of cytomegalovirus (CMV) viral load (VL) by day 100 and overall survival (OS) at 1-year after hematopoietic cell transplantation (HCT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In a retrospective cohort study, including patients receiving HCT between June 2010 and December 2017 from Memorial Sloan Kettering Cancer Center, AAUC was calculated for patients with detected VL. Patients were categorized into non-controllers (Q4) and controllers (Q1\u2013Q3) using the highest AAUC quartile as cutoff. Cox models were used to estimate the association between AAUC and OS. Patients with non-detected CMV VL were categorized into elite-controllers (recipient+ [R+] or R\u2212\/donor+ [D+]) and R\u2212\/D\u2212.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study (N = 952) included 282 controllers, 93 non-controllers, 275 elite-controllers, and 302 R\u2212\/D\u2212. OS was 80.1% and 58.1% for controllers and non-controllers, respectively. In multivariable models, non-controllers had worse OS versus controllers (adjusted hazard ratio [HR] = 2.65; 95% confidence interval [CI], 1.71\u20134.12). In landmark analyses, controllers had similar OS as elite-controllers (HR = 1.26; 95% CI, .83\u20131.91) or R\u2212\/D\u2212 (HR = 0.98; 95% CI, .64\u20131.5).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Non-controllers had worse OS 1-year post-HCT. Controllers had similar OS as elite-controllers or R\u2212\/D\u2212. Future studies are needed to validate our AAUC cutoff across different cohorts and CMV management strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiab212","type":"journal-article","created":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T07:25:14Z","timestamp":1618385114000},"page":"620-631","source":"Crossref","is-referenced-by-count":22,"title":["Cytomegalovirus Viral Load Kinetics Predict Cytomegalovirus End-Organ Disease and Mortality After Hematopoietic Cell Transplant"],"prefix":"10.1093","volume":"224","author":[{"given":"Anat","family":"Stern","sequence":"first","affiliation":[{"name":"Infectious Disease Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqi","family":"Su","sequence":"additional","affiliation":[{"name":"Infectious Disease Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Dumke","sequence":"additional","affiliation":[{"name":"Infectious Disease Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Fang","sequence":"additional","affiliation":[{"name":"Infectious Disease Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roni","family":"Tamari","sequence":"additional","affiliation":[{"name":"Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA"},{"name":"Weill Cornell Medical College, Cornell University, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Jakubowski","sequence":"additional","affiliation":[{"name":"Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA"},{"name":"Weill Cornell Medical College, Cornell University, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Cho","sequence":"additional","affiliation":[{"name":"Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA"},{"name":"Weill Cornell Medical College, Cornell University, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Giralt","sequence":"additional","affiliation":[{"name":"Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA"},{"name":"Weill Cornell Medical College, Cornell University, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[{"name":"Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA"},{"name":"Weill Cornell Medical College, Cornell University, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genovefa A","family":"Papanicolaou","sequence":"additional","affiliation":[{"name":"Infectious Disease Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA"},{"name":"Weill Cornell Medical College, Cornell University, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,4,17]]},"reference":[{"key":"2021081613472041600_CIT0001","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2003-10-3616","article-title":"The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy","volume":"103","author":"Boeckh","year":"2004","journal-title":"Blood"},{"key":"2021081613472041600_CIT0002","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1182\/blood-2013-05-499830","article-title":"CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT","volume":"122","author":"Schmidt-Hieber","year":"2013","journal-title":"Blood"},{"key":"2021081613472041600_CIT0003","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1007\/s00277-019-03669-z","article-title":"The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMT","volume":"98","author":"Schmidt-Hieber","year":"2019","journal-title":"Ann Hematol"},{"key":"2021081613472041600_CIT0004","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","article-title":"Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study","volume":"3","author":"Green","year":"2016","journal-title":"Lancet Haematol"},{"key":"2021081613472041600_CIT0005","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood"},{"key":"2021081613472041600_CIT0006","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/cid\/cix804","article-title":"Kinetics of double-stranded DNA viremia after allogeneic hematopoietic cell transplantation","volume":"66","author":"Hill","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2021081613472041600_CIT0007","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/S0140-6736(00)02350-3","article-title":"Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation","volume":"355","author":"Emery","year":"2000","journal-title":"Lancet"},{"key":"2021081613472041600_CIT0008","doi-asserted-by":"crossref","first-page":"e133960","DOI":"10.1172\/JCI133960","article-title":"CMV viral load kinetics as surrogate endpoints after allogeneic transplantation","volume":"131","author":"Duke","year":"2021","journal-title":"J Clin Invest"},{"key":"2021081613472041600_CIT0009","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.bbmt.2017.11.038","article-title":"Impact of cytomegalovirus viral load on probability of spontaneous clearance and response to preemptive therapy in allogeneic stem cell transplantation recipients","volume":"24","author":"Camargo","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021081613472041600_CIT0010","doi-asserted-by":"crossref","first-page":"S327","DOI":"10.1016\/j.bbmt.2019.12.352","article-title":"CMV viral load kinetics as surrogate endpoints for antiviral prophylaxis trials","volume":"26","author":"Duke","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021081613472041600_CIT0011","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"2021081613472041600_CIT0012","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.bbmt.2018.09.038","article-title":"A randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation","volume":"25","author":"Marty","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021081613472041600_CIT0013","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/cid\/ciz490","article-title":"A mortality analysis of letermovir prophylaxis for cytomegalovirus (CMV) in CMV-seropositive recipients of allogeneic hematopoietic cell transplantation","volume":"70","author":"Ljungman","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021081613472041600_CIT0014","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/infdis\/jiaa237","article-title":"Adenovirus viral kinetics and mortality in ex-vivo T-cell depleted hematopoietic cell transplant recipients with adenovirus infection from a single center","volume":"222","author":"Lee","year":"2020","journal-title":"J Infect Dis"},{"key":"2021081613472041600_CIT0015","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/bmt.2016.36","article-title":"A novel reduced intensity conditioning regimen for patients with high-risk hematological malignancies undergoing allogeneic stem cell transplantation","volume":"51","author":"Hobbs","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"2021081613472041600_CIT0016","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.bbmt.2019.10.003","article-title":"Ex vivo T cell-depleted hematopoietic stem cell transplantation for adult patients with acute myelogenous leukemia in first and second remission: long-term disease-free survival with a significantly reduced risk of graft-versus-host disease","volume":"26","author":"Montoro","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021081613472041600_CIT0017","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1046\/j.1365-2141.1997.1112925.x","article-title":"IBMTR severity index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade","volume":"97","author":"Rowlings","year":"1997","journal-title":"Br J Haematol"},{"key":"2021081613472041600_CIT0018","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.bbmt.2020.03.019","article-title":"Impact of preemptive therapy for cytomegalovirus on toxicities after allogeneic hematopoietic cell transplantation in clinical practice: a retrospective single-center cohort study","volume":"26","author":"Zavras","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021081613472041600_CIT0019","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jinf.2014.06.004","article-title":"Impact of peri-transplant vancomycin and fluoroquinolone administration on rates of bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients: a 12-year single institution study","volume":"69","author":"Seo","year":"2014","journal-title":"J Infect"},{"key":"2021081613472041600_CIT0020","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1128\/JCM.03435-14","article-title":"Monitoring of cytomegalovirus viral loads by two molecular assays in whole-blood and plasma samples from hematopoietic stem cell transplant recipients","volume":"53","author":"Babady","year":"2015","journal-title":"J Clin Microbiol"},{"key":"2021081613472041600_CIT0021","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1038\/s41409-019-0483-7","article-title":"Association between adenovirus viral load and mortality in pediatric allo-HCT recipients: the multinational advance study","volume":"54","author":"Zecca","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"2021081613472041600_CIT0022","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2021081613472041600_CIT0023","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.bbmt.2007.08.047","article-title":"A scheme for defining cause of death and its application in the T cell depletion trial","volume":"13","author":"Copelan","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021081613472041600_CIT0024","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/tri.13081","article-title":"An unjustified benefit: immortal time bias in the analysis of time-dependent events","volume":"31","author":"Gleiss","year":"2018","journal-title":"Transpl Int"},{"key":"2021081613472041600_CIT0025","doi-asserted-by":"crossref","first-page":"e13387","DOI":"10.1111\/tid.13387","article-title":"Association between the kinetics of cytomegalovirus reactivation evaluated in terms of the area under the curve of cytomegalovirus antigenemia and invasive mold infection during the post-engraftment phase after allogeneic hematopoietic stem cell transplantation","volume":"22","author":"Kimura","year":"2020","journal-title":"Transpl Infect Dis"},{"key":"2021081613472041600_CIT0026","doi-asserted-by":"crossref","first-page":"104373","DOI":"10.1016\/j.jcv.2020.104373","article-title":"Burden of adenoviraemia predicts survival in paediatric recipients of allogeneic haematopoietic stem cell transplant","volume":"127","author":"Deambrosis","year":"2020","journal-title":"J Clin Virol"},{"key":"2021081613472041600_CIT0027","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2016-10-748426","article-title":"The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality","volume":"129","author":"Hill","year":"2017","journal-title":"Blood"},{"key":"2021081613472041600_CIT0028","doi-asserted-by":"crossref","first-page":"ofz003","DOI":"10.1093\/ofid\/ofz003","article-title":"Correlation of cytomegalovirus (CMV) disease severity and mortality with CMV viral burden in CMV-seropositive donor and CMV-seronegative solid organ transplant recipients","volume":"6","author":"McBride","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2021081613472041600_CIT0029","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/cid\/ciy138","article-title":"Cytomegalovirus DNAemia burden and mortality following allogeneic hematopoietic stem cell transplantation: an area under a curve-based investigational approach","volume":"67","author":"Gim\u00e9nez","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2021081613472041600_CIT0030","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1182\/blood-2013-02-487074","article-title":"CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia","volume":"122","author":"Green","year":"2013","journal-title":"Blood"},{"key":"2021081613472041600_CIT0031","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1182\/blood-2002-05-1496","article-title":"Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors","volume":"100","author":"Marr","year":"2002","journal-title":"Blood"},{"key":"2021081613472041600_CIT0032","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1086\/338624","article-title":"High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection","volume":"185","author":"Nichols","year":"2002","journal-title":"J Infect Dis"},{"key":"2021081613472041600_CIT0033","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1080\/10428194.2016.1265113","article-title":"Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplant","volume":"58","author":"Goldberg","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"2021081613472041600_CIT0034","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood.V93.2.467","article-title":"Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions","volume":"93","author":"Small","year":"1999","journal-title":"Blood"},{"key":"2021081613472041600_CIT0035","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1182\/blood-2014-07-589150","article-title":"CMV promotes recipient T-cell immunity following reduced-intensity T-cell-depleted HSCT, significantly modulating chimerism status","volume":"125","author":"Sellar","year":"2015","journal-title":"Blood"},{"key":"2021081613472041600_CIT0036","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.bbmt.2017.03.027","article-title":"Possible impact of cytomegalovirus-specific CD8+ T cells on immune reconstitution and conversion to complete donor chimerism after allogeneic stem cell transplantation","volume":"23","author":"Ogonek","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021081613472041600_CIT0037","doi-asserted-by":"crossref","first-page":"S326","DOI":"10.1016\/j.bbmt.2018.12.527","article-title":"Cytomegalovirus reactivation promotes CD8+ T cell subset recovery after unmodified allogeneic hematopoietic cell transplantation","volume":"25","author":"Jain","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021081613472041600_CIT0038","first-page":"2365","article-title":"Cytomegalovirus (CMV) cell-mediated immunity and cmv infection after allogeneic hematopoietic cell transplantation: the REACT study","volume":"71","author":"Chemaly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021081613472041600_CIT0039","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.bbmt.2016.05.003","article-title":"Cytomegalovirus infection after CD34+-selected hematopoietic cell transplantation","volume":"22","author":"Huang","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021081613472041600_CIT0040","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/j.bbmt.2020.06.025","article-title":"Impact of preemptive therapy for cytomegalovirus on hospitalizations and cost after hematopoietic stem cell transplantation","volume":"26","author":"Fang","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021081613472041600_CIT0041","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMoa1714656","article-title":"Maribavir for preemptive treatment of cytomegalovirus reactivation","volume":"381","author":"Maertens","year":"2019","journal-title":"N Engl J Med"},{"key":"2021081613472041600_CIT0042","doi-asserted-by":"crossref","first-page":"S638","DOI":"10.1093\/ofid\/ofz360.1605","article-title":"1742. kinetics of CMV viremia with letermovir prophylaxis in the first 100 days post hematopoietic cell transplantation (HCT): a single-center experience","volume":"6","author":"Zavras","year":"2019","journal-title":"Open Forum Infect Dis"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiab212\/39449872\/jiab212.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/224\/4\/620\/39761094\/jiab212.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/224\/4\/620\/39761094\/jiab212.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T09:49:07Z","timestamp":1629107347000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/224\/4\/620\/6232014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,17]]},"references-count":42,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4,17]]},"published-print":{"date-parts":[[2021,8,16]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiab212","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,8,15]]},"published":{"date-parts":[[2021,4,17]]}}}